**[*HOSPITAL NAME*] Acquires New BioFire FilmArray™ Blood Culture Identification Test**

**SALT LAKE CITY, Utah,** (Month XX, 2014) – [*HOSPITAL NAME*] announced today that it has acquired BioFire Diagnostics’ FilmArray Blood Culture Identification (BCID) Panel. The 27-target panel is the most comprehensive blood culture test to be cleared by the FDA.

The FilmArray BCID Panel provides results from positive blood cultures, and can identify more than 100 blood pathogens known to cause sepsis. For each hour that severe sepsis goes untreated, the average mortality rate increases by 7.6 percent, making timely diagnosis and administration of appropriate therapy imperative for positive patient outcomes.

The BCID Panel is designed to help hospitals identify bloodstream infection-causing organisms more rapidly than conventional identification methods. Rapid identification of pathogens in positive blood cultures has been shown to reduce mortality rates, shorten hospital stays and lower overall costs due to sepsis.

“We have made it a top priority this year to significantly reduce deaths caused by sepsis, and we plan to use the FilmArray BCID test to help us achieve this goal,” said [*HOSPITAL SPOKESPERSON, TITLE*]. “The faster we get test results, the faster we will be able to apply an optimized treatment plan, thus improving overall patient outcomes including reduced deaths, costs and the length of patient hospital stays.”

“Customer feedback on the BCID Panel has been extremely positive. There is a lot of excitement for this product among our clinical hospital laboratory customers and anticipation for the effect it will likely have on antibiotic stewardship, patient care and cost reduction,” said Randy Rasmussen, CEO of BioFire Diagnostics. “We view this panel as a game-changer in the diagnosis of bloodstream infections, of which will aid clinicians with treatment decisions for their patients.”

With an easy procedure requiring only two minutes of hands-on time, the BCID Panel can identify a pathogen in nine out of 10 positive blood cultures in about an hour, and is the only test that provides results for gram-positive bacteria, gram-negative bacteria and yeast that cause bloodstream infections.

In addition, the panel includes the first FDA cleared diagnostic test for the *bla*KPC gene, which is linked to carbapenem resistance in Klebsiella pneumoniae, Acinetobacter spp and Carbapenem-resistant Enterobacteriaceae (CRE). Bloodstream infections with CREs are reported to kill up to 50 percent of infected patients. The BCID Panel also tests for common antimicrobial resistance genes associated with Methicillin-resistant *Staphylococcus* *aureus* (MRSA) and Vancomycin-resistant Enterococci (VRE).

**About BioFire Diagnostics, LLC**

BioFire Diagnostics, LLC, a wholly owned subsidiary of bioMérieux, Inc., manufactures and distributes the user-friendly FilmArray System to hospital-based clinical laboratories across the U.S. and EU. BioFire currently offers the FDA-cleared and CE IVD marked FilmArray Respiratory Panel and FilmArray Blood Culture Identification Panel. The company continues to broaden its FilmArray test menu with regulatory applications and ongoing development of novel panels.

BioFire holds more than 85 patents related to polymerase chain reaction (PCR), and has used its extensive patent portfolio to successfully market nearly 200 products to the clinical, research and military markets. BioFire customers include the Department of Health and Human Services, the Department of Defense, state and local law enforcement and researchers and medical technicians across a spectrum of fields and industries.

For further information, please visit [www.BioFireDx.com](http://www.BioFireDx.com).

# # #

**Contact**:

BioFire Diagnostics, LLC

Mari Hoidal

801-736-6354 x774

[Mari.Hoidal@biofiredx.com](mailto:Mari.Hoidal@biofiredx.com)